Impact Review 2025

See our latest review

Impact is not a separate consideration — it is part of what makes these businesses sound investments.

Shifting trade dynamics, the disruptive effects of AI on economies and labour markets, and sustained geopolitical uncertainty made 2025 a year that required careful navigation. Against that backdrop, we have remained constructive on the opportunity set across Asia while being deliberate about how we deploy. The businesses we back are addressing structural demand in energy transition, financial access, and healthcare, and that gives us confidence in their resilience over time.

David HengCEO, ABC Impact

Over the long run, the most durable investment opportunities tend to be those where financial returns and social outcomes point in the same direction.

Asia sits at the centre of this — it is where the energy transition is most urgent, where financial access can unlock the most productivity, and where healthcare innovation can reach the most people.

At ABC Impact, we invest in companies that are building commercially viable, scalable solutions in each of these areas. Businesses that are genuinely needed tend to be more resilient, and the impact they generate tends to be more lasting. The two reinforce each other.

Goh Yew LinChairman, ABC Impact

Impact investing is not about trade-offs—it is about unlocking
value where markets and societies need solutions most.

Impact Achieved in 2025

Climate

tonnes of emissions avoided

2000000

Social

total individuals reached

48000000

Healthcare

total patients reached

5000000

Education

total stakeholders reached

22000000

Financial Inclusion

individuals & MSMEs reached

7000000

Agriciulture

total farmers reached

12000000

Employment

Individuals employed

30000

OTHER ENVIRONMENTAL IMPACTS

tonnes of fugitive plastic pollution avoided

4000

tonnes of food waste avoided

40000

tonnes of fishing avoided

15000

litres of water saved

57000000000

New investments from ABC Impact Fund II

AC Health

COMPANY OVERVIEW

AC Health is an integrated healthcare platform in the Philippines, operating across both provider and pharmaceutical segments. As one of the emerging business units of Ayala Corporation, the business spans hospitals, clinics, retail pharmacies and pharmaceutical distribution, forming a nationwide network across the patient care continuum.

Its provider segment includes a network of primary and specialty clinics alongside secondary and tertiary hospitals, while its pharma segment comprises importation, wholesale distribution and a national retail pharmacy network. Together, these capabilities position AC Health as an end-to-end platform delivering coordinated care across multiple points of access.

LIVES TOUCHED THROUGH AC HEALTH’S NETWORK

1 M

IMPACT THESIS

Strengthening health system capacity and coverage in the Philippines through an integrated provider and pharma platform, by enhancing availability, affordability and quality of care for better population health.

DCDC Kidney Care

COMPANY OVERVIEW

DCDC Kidney Care is one of India’s largest dialysis providers and the leading operator within the public–private partnership (PPP) segment. The company focuses on delivering life-sustaining dialysis treatment for patients with end-stage renal disease (ESRD), with a particular emphasis on underserved populations across Tier III cities and beyond.

It operates a network of dialysis centres across multiple states through a combination of PPP arrangements with public hospitals, standalone centres, and partnerships with private hospitals, enabling it to serve patients across different income segments and care settings.

PATIENTS RECEIVED DIALYSIS CARE SINCE INVESTMENT

40000

RECEIVED FULLY SUBSIDISED TREATMENT

10 %

CENTRES ACROSS INDIA

100

ARE ESTABLISHED THROUGH PPP ARRANGEMENTS

10 %

IMPACT THESIS

Strengthening India’s health system capacity to deliver quality dialysis care by reducing availability and affordability barriers for underserved segments, enabling improved clinical and health outcomes.

HistoSonics

COMPANY OVERVIEW

HistoSonics is a global MedTech company advancing histotripsy in oncological therapy – a non-invasive, ultrasound-based therapy that mechanically destroys targeted tumour tissue. Its Edison platform received U.S. FDA De Novo approval in October 2023 for the treatment of liver tumours, following demonstrated technical success rates of 95.5%.

Unlike conventional thermal or surgical approaches, histotripsy uses focused ultrasound to mechanically disrupt tissue, representing a distinct mechanism of action with potential clinical advantages in precision and safety.

PATIENTS PROVIDED WITH HISTOTRIPSY PROCEDURE

1000 +

IMPACT THESIS

Pioneering a tumour therapy
option with enhanced precision and safety with reduced risk of adverse effects, addressing treatment access barriers for higher-risk patients, while fostering innovation in the onco- therapeutic space.

NeuroGen

COMPANY OVERVIEW

NeuroGen is an integrated pharmaceutical platform focused on central nervous system (CNS) therapies in China, addressing a broad range of neurological conditions including epilepsy, Parkinson’s disease and allergies.

Originating from UCB’s China operations and now independently established, the company combines a portfolio of established therapies with manufacturing and distribution capabilities. This provides a stable operating base while supporting continued expansion through in- licensing and pipeline development.

PATIENTS RECEIVED THROUGH NEUROGEN’S ANTI-EPILEPTIC SOLUTIONS SINCE INVESTMENT

300000

IMPACT THESIS

Driving better health and quality-of- life outcomes for patients in China through its portfolio of safe and efficacious CNS medicines, while strengthening pharmaceutical supply chains to improve drug availability in the country.

Vistaar Finance

COMPANY OVERVIEW

Founded in 2010, Vistaar Finance is a non-banking financial company (NBFC) providing secured lending solutions to micro, small and medium enterprises (MSMEs) across India. The company operates through a network of nearly 300 branches spanning rural and semi-urban regions, serving businesses across sectors including trading, services, manufacturing and hospitality.

Its product suite includes small- and medium-ticket business loans, affordable housing loans and gold loans, enabling it to support borrowers across different stages of their business lifecycle. This diversified, secured lending model provides both stability and flexibility in addressing a wide range of financing needs.

LIVES TOUCHED THROUGH VISTAAR’S FINANCIAL PRODUCTS SINCE INVESTMENT

100000

BORROWERS REACHED SINCE INVESTMENT

60000

IMPACT THESIS

Enhancing business productivity and improving livelihoods of small business owners in India, through better availability of timely and affordable credit.

About ABC Impact

We are a private equity firm dedicated to impact investing. Headquartered in Singapore, we invest in companies generating meaningful impact and creating positive change in Asia.

INTEGRATING IMPACT INTO INVESTMENTS

We adopt a proprietary impact measurement and management system that is integrated into our investment process. This helps us monitor impact performance and ensure portfolio companies deliver impact outcomes, alongside financial returns. Through evidence-based research and industry-aligned metrics, we invest in companies whose products and services help advance the UN Sustainable Development Goals.

A DIVERSE TEAM

We are a diverse team of professionals who understands Asia and its vast potential for impact at scale. With cross-functional expertise and experience from impact investing, private equity, portfolio management, legal, and non-governmental organisations, we are united in the mission to make a difference to our environment and the communities in Asia.

INSIGHTS

Fostering impact at scale through private capital

As part of our mission, we develop insightful studies, commission independent research, and share our perspectives on various environmental and social impact challenges around the world.

What We Invest In

Acceleration & Growth Stage

We primarily invest in impact-driven companies seeking capital to finance early growth and expansion.

Impactful

We focus on founders and companies with strong impact intentionality, driving outcomes in line with the UN Sustainable Development Goals.

Asia Focused

We seek to support companies whose products and services have the potential to address Asia’s biggest challenges.

OUTCOMES

A Growing Portfolio

A global mandate, with an Asia focus

INVESTMENT THEMES

We focus on thematic areas that can reframe the region’s most pressing environmental and social challenges into growth and development opportunities.

Climate & Water
Solutions

Financial & Digital Inclusion

Better Healthcare & Education

Sustainable Food & Agriculture

Learn More

Impact investing is not about trade-offs—it is about unlocking
value where markets and societies need solutions most.

Impact Achieved in 2025